Role of interstitial inflammation in the pathogenesis of polycystic kidney disease

Nephrology

Volumn 18, Issue 5, 2013, Pages 317-330

  Ta, Michelle H T ^a   Harris, David C H ^a   Rangan, Gopala K ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

inflammation; macrophage; nuclear factor B; polycystic kidney disease; tumour necrosis factor

Indexed keywords

AUTACOID; CHEMOATTRACTANT; CONJUGATED LINOLEIC ACID; CURCUMIN; ENALAPRIL; ETANERCEPT; INTERLEUKIN 1BETA; INTERLEUKIN 2; JANUS KINASE; METHYLPREDNISOLONE; MONOCYTE CHEMOTACTIC PROTEIN 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; OLMESARTAN; OSTEOPONTIN; PIOGLITAZONE; POLYCYSTIN 1; POLYCYSTIN 2; RAPAMYCIN; ROSIGLITAZONE; STAT PROTEIN; TELMISARTAN; TRIPTOLIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; UNCLASSIFIED DRUG; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V2 RECEPTOR; VASOPRESSIN V2 RECEPTOR ANTAGONIST;

B LYMPHOCYTE; BASOPHIL; CELL FUNCTION; CYTOKINE PRODUCTION; DENDRITIC CELL; DIET THERAPY; DISEASE COURSE; GENE MUTATION; GENETIC SUSCEPTIBILITY; HUMAN; HYPERTENSION; IMMUNOPHENOTYPING; INFLAMMATORY CELL; INFLAMMATORY INFILTRATE; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY INJURY; KIDNEY INTERSTITIUM; KIDNEY POLYCYSTIC DISEASE; MACROPHAGE; MAST CELL; MONOCYTE; MONONUCLEAR PHAGOCYTE; NEPHRITIS; NEUTROPHIL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CYTOKINES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; MACROPHAGES; MUTATION; NF-KAPPA B; OSTEOPONTIN; PHAGOCYTES; POLYCYSTIC KIDNEY DISEASES;

EID: 84876476059     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/nep.12045     Document Type: Review

References (153)

1. Harris PC, Torres VE,. Polycystic kidney disease. Annu. Rev. Med. 2009; 60: 321-337.
2. Hughes J, Ward CJ, Peral B, et al. The polycystic kidney disease 1 (PKD1) gene encodes a novel protein with multiple cell recognition domains. Nat. Genet. 1995; 10: 151-160.
3. Mochizuki T, Wu G, Hayashi T, et al. PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein. Science 1996; 272: 1339-1342.
4. Ward CJ, Hogan MC, Rossetti S, et al. The gene mutated in autosomal recessive polycystic kidney disease encodes a large, receptor-like protein. Nat. Genet. 2002; 30: 259-269.
5. Gardner KD,. Pathogenesis of human cystic renal disease. Annu. Rev. Med. 1988; 39: 185-191.
6. Blyth H, Ockenden BG,. Polycystic disease of kidney and liver presenting in childhood. J. Med. Genet. 1971; 8: 257-284.
7. Grantham JJ, Mulamalla S, Swenson-Fields KI,. Why kidneys fail in autosomal dominant polycystic kidney disease. Nat. Rev. Nephrol. 2011; 7: 556-566.
8. Ye M, Grantham JJ,. The secretion of fluid by renal cysts from patients with autosomal dominant polycystic kidney disease. N. Engl. J. Med. 1993; 329: 310-313.
9. Wilson PD, Hreniuk D, Gabow PA,. Abnormal extracellular matrix and excessive growth of human adult polycystic kidney disease epithelia. J. Cell. Physiol. 1992; 150: 360-369.
10. Zeier M, Fehrenbach P, Geberth S, Mohring K, Waldherr R, Ritz E,. Renal histology in polycystic kidney disease with incipient and advanced renal failure. Kidney Int. 1992; 42: 1259-1265.
11. Ibrahim S,. Increased apoptosis and proliferative capacity are early events in cyst formation in autosomal-dominant, polycystic kidney disease. ScientificWorldJournal 2007; 7: 1757-1767.
12. Rees AJ,. Monocyte and macrophage biology: An overview. Semin. Nephrol. 2010; 30: 216-233.
13. Li L, Huang L, Sung S-SJ, et al. The chemokine receptors CCR2 and CX3CR1 mediate monocyte/macrophage trafficking in kidney ischemia-reperfusion injury. Kidney Int. 2008; 74: 1526-1537.
14. Nelson PJ, Rees AJ, Griffin MD, Hughes J, Kurts C, Duffield J,. The renal mononuclear phagocytic system. J. Am. Soc. Nephrol. 2012; 23: 194-203.
15. Lim AKH, Tesch GH,. Inflammation in diabetic nephropathy. Mediators Inflamm. 2012; 2012: Article ID 146154.
16. Praga M, Gonzalez E,. Acute interstitial nephritis. Kidney Int. 2010; 77: 956-961.
17. Lin SL, Castaño AP, Nowlin BT, Lupher ML, Duffield JS,. Bone marrow Ly6Chigh monocytes are selectively recruited to injured kidney and differentiate into functionally distinct populations. J. Immunol. 2009; 183: 6733-6743.
18. Ashizawa M, Miyazaki M, Furusu A, et al. Nephronophthisis in two siblings. Clin. Exp. Nephrol. 2005; 9: 320-325.
19. Karihaloo A, Koraishy F, Huen S, et al. Macrophages promote cyst growth in polycystic kidney disease. J. Am. Soc. Nephrol. 2011; 22: 1809-1814.
20. Park EY, Seo MJ, Park JH,. Effects of specific genes activating RAGE on polycystic kidney disease. Am. J. Nephrol. 2010; 32: 169-178.
21. Hou X, Mrug M, Yoder BK, et al. Cystin, a novel cilia-associated protein, is disrupted in the cpk mouse model of polycystic kidney disease. J. Clin. Invest. 2002; 109: 533-540.
22. Fry JL Jr, Koch WE, Jennette JC, McFarland E, Fried FA, Mandell J,. A genetically determined murine model of infantile polycystic kidney disease. J. Urol. 1985; 134: 828-833.
23. Zhou J, Ouyang X, Cui X, et al. Renal CD14 expression correlates with the progression of cystic kidney disease. Kidney Int. 2010; 78: 550-560.
24. Nakamura T, Ebihara I, Fukui M, et al. Increased endothelin and endothelin receptor mRNA expression in polycystic kidneys of cpk mice. J. Am. Soc. Nephrol. 1993; 4: 1064-1072.
25. Olbrich H, Fliegauf M, Hoefele J, et al. Mutations in a novel gene, NPHP3, cause adolescent nephronophthisis, tapeto-retinal degeneration and hepatic fibrosis. Nat. Genet. 2003; 34: 455-459.
26. Takahashi H, Calvet JP, Dittemore-Hoover D, Yoshida K, Grantham JJ, Gattone VH,. A hereditary model of slowly progressive polycystic kidney disease in the mouse. J. Am. Soc. Nephrol. 1991; 1: 980-989.
27. Nakamura T, Ebihara I, Nagaoka I, et al. Growth factor gene expression in kidney of murine polycystic kidney disease. J. Am. Soc. Nephrol. 1993; 3: 1378-1386.
28. Rodriguez-Iturbe B, Pons H, Herrera-Acosta J, Johnson RJ,. Role of immunocompetent cells in nonimmune renal diseases. Kidney Int. 2001; 59: 1626-1640.
29. Upadhya P, Birkenmeier EH, Birkenmeier CS, Barker JE,. Mutations in a NIMA-related kinase gene, Nek1, cause pleiotropic effects including a progressive polycystic kidney disease in mice. Proc. Natl Acad. Sci. U.S.A. 2000; 97: 217-221.
30. Vogler C, Homan S, Pung A, et al. Clinical and pathologic findings in two new allelic murine models of polycystic kidney disease. J. Am. Soc. Nephrol. 1999; 10: 2534-2539.
31. McCooke J, Appels R, Barrero R, et al. A novel mutation causing nephronophthisis in the Lewis polycystic kidney rat localises to a conserved RCC1 domain in Nek8. BMC Genomics 2012; 13: 393-408.
32. Phillips JK, Hopwood D, Loxley RA, et al. Temporal relationship between renal cyst development, hypertension and cardiac hypertrophy in a new rat model of autosomal recessive polycystic kidney disease. Kidney Blood Press. Res. 2007; 30: 129-144.
33. Guay-Woodford LM, Desmond RA,. Autosomal recessive polycystic kidney disease: The clinical experience in North America. Pediatrics 2003; 111: 1072-1080.
34. Schafer K, Gretz N, Bader M, et al. Characterization of the Han:SPRD rat model for hereditary polycystic kidney disease. Kidney Int. 1994; 46: 134-152.
35. Cowley BD Jr, Ricardo SD, Nagao S, Diamond JR,. Increased renal expression of monocyte chemoattractant protein-1 and osteopontin in ADPKD in rats. Kidney Int. 2001; 60: 2087-2096.
36. Kaspareit-Rittinghausen J, Rapp K, Deerberg F, Wcislo A, Messow C,. Hereditary polycystic kidney disease associated with osteorenal syndrome in rats. Vet. Pathol. 1989; 26: 195-201.
37. Mrug M, Zhou J, Woo Y, et al. Overexpression of innate immune response genes in a model of recessive polycystic kidney disease. Kidney Int. 2008; 73: 63-76.
38. Gordon S,. Alternative activation of macrophages. Nat. Rev. Immunol. 2003; 3: 23-35.
39. Riera M, Burtey S, Fontes M,. Transcriptome analysis of a rat PKD model: Importance of genes involved in extracellular matrix metabolism. Kidney Int. 2006; 69: 1558-1563.
40. Cowley BD Jr, Gudapaty S, Kraybill AL, et al. Autosomal-dominant polycystic kidney disease in the rat. Kidney Int. 1993; 43: 522-534.
41. Lee S, Huen S, Nishio H, et al. Distinct macrophage phenotypes contribute to kidney injury and repair. J. Am. Soc. Nephrol. 2011; 22: 317-326.
42. Abbas A, Lichtman A, Pober J,. Cytokines. Cells and Tissues of the Immune System (chapter 2). In: Cellular and Molecular Immunology. Philadelphia: WB Saunders Company, 2000; 17-38.
43. Duffield JS,. Macrophages and Immunologic Inflammation of the Kidney. Semin. Nephrol. 2010; 30: 234-254.
44. Ricardo SD, Van Goor H, Eddy AA,. Macrophage diversity in renal injury and repair. J. Clin. Invest. 2008; 118: 3522-3530.
45. Segura E, Villadangos JA,. Antigen presentation by dendritic cells in vivo. Curr. Opin. Immunol. 2009; 21: 105-110.
46. Dong X, Swaminathan S, Bachman LA, Croatt AJ, Nath KA, Griffin MD,. Resident dendritic cells are the predominant TNF-secreting cell in early renal ischemia-reperfusion injury. Kidney Int. 2007; 71: 619-628.
47. Kim M-G, Su Boo C, Sook Ko Y, et al. Depletion of kidney CD11c+ F4/80+ cells impairs the recovery process in ischaemia/reperfusion-induced acute kidney injury. Nephrol. Dial. Transplant. 2010; 25: 2908-2921.
48. Heller F, Lindenmeyer MT, Cohen CD, et al. The contribution of B cells to renal interstitial inflammation. Am. J. Pathol. 2007; 170: 457-468.
49. Ysebaert DK, De Greef KE, De Beuf A, et al. T cells as mediators in renal ischemia-reperfusion injury. Kidney Int. 2004; 66: 491-496.
50. Kurts C, Heymann F, Lukacs-Kornek V, Boor P, Floege J,. Role of T cells and dendritic cells in glomerular immunopathology. Semin. Immunopathol. 2007; 29: 317-335.
51. Wolf D, Hochegger K, Wolf AM, et al. CD4+ CD25+ regulatory T cells inhibit experimental anti-glomerular basement membrane glomerulonephritis in mice. J. Am. Soc. Nephrol. 2005; 16: 1360-1370.
52. Fox L, Hegde S, Gumperz JE,. Natural killer T cells: Innate lymphocytes positioned as a bridge between acute and chronic inflammation? Microbes Infect. 2010; 12: 1125-1133.
53. Coquet JM, Chakravarti S, Kyparissoudis K, et al. Diverse cytokine production by NKT cell subsets and identification of an IL-17-producing CD4-NK1.1- NKT cell population. Proc. Natl Acad. Sci. U.S.A. 2008; 105: 11287-11292.
54. Li L, Huang L, Sung SJ, et al. NKT cell activation mediates neutrophil IFN-γ production and renal ischemia-reperfusion injury. J. Immunol. 2007; 178: 5899-5911.
55. Burne-Taney MJ, Ascon DB, Daniels F, Racusen L, Baldwin W, Rabb H,. B cell deficiency confers protection from renal ischemia reperfusion injury. J. Immunol. 2003; 171: 3210-3215.
56. Renner B, Strassheim D, Amura CR, et al. B cell subsets contribute to renal injury and renal protection after ischemia/reperfusion. J. Immunol. 2010; 185: 4393-4400.
57. Bouaziz J-D, Yanaba K, Tedder TF,. Regulatory B cells as inhibitors of immune responses and inflammation. Immunol. Rev. 2008; 224: 201-214.
58. Holdsworth SR, Summers SA,. Role of mast cells in progressive renal diseases. J. Am. Soc. Nephrol. 2008; 19: 2254-2261.
59. Theoharides TC, Alysandratos K-D, Angelidou A, et al. Mast cells and inflammation. Biochim. Biophys. Acta, Mol. Basis Dis. 2012; 1822: 21-33.
60. Summers SA, Chan J, Gan P-Y, et al. Mast cells mediate acute kidney injury through the production of TNF. J. Am. Soc. Nephrol. 2011; 22: 2226-2236.
61. Summers SA, Gan P-, Dewage L, et al. Mast cell activation and degranulation promotes renal fibrosis in experimental unilateral ureteric obstruction. Kidney Int. 2012; 82: 676-685.
62. McPherson EA, Luo Z, Brown RA, et al. Chymase-like angiotensin II-generating activity in end-stage human autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 2004; 15: 493-500.
63. Kinsey G, Okusa M,. Role of leukocytes in the pathogenesis of acute kidney injury. Crit. Care 2012; 16: 214.
64. Awad AS, Rouse M, Huang L, et al. Compartmentalization of neutrophils in the kidney and lung following acute ischemic kidney injury. Kidney Int. 2009; 75: 689-698.
65. Bolisetty S, Agarwal A,. Neutrophils in acute kidney injury: Not neutral any more. Kidney Int. 2009; 75: 674-676.
66. Bernhardt WM, Wiesener MS, Weidemann A, et al. Involvement of hypoxia-inducible transcription factors in polycystic kidney disease. Am. J. Pathol. 2007; 170: 830-842.
67. O'Leary CA, Mackay BM, Malik R, Edmondston JE, Robinson WF, Huxtable CR,. Polycystic kidney disease in bull terriers: An autosomal dominant inherited disorder. Aust. Vet. J. 1999; 77: 361-366.
68. Schneider E, Thieblemont N, De Moraes ML, Dy M,. Basophils: New players in the cytokine network. Eur. Cytokine Netw. 2010; 21: 1421-1453.
69. Stone KD, Prussin C, Metcalfe DD,. IgE, mast cells, basophils, and eosinophils. J. Allergy Clin. Immunol. 2010; 125: S73-80.
70. Mack M, Rosenkranz AR,. Basophils and mast cells in renal injury. Kidney Int. 2009; 76: 1142-1147.
71. Ascon D, Ascon M,. Mechanisms of T lymphocytes in the damage and repair long term after renal ischemia reperfusion injury. In:, Trzcinska M, (ed.). Kidney Transplantation-New Perspectives. Rijeka: InTech Europe, 2011; 1-14.
72. Nadel JA,. Biology of mast cell tryptase and chymase. Ann. N. Y. Acad. Sci. 1991; 629: 319-331.
73. Tani K, Ogushi F, Kido H, et al. Chymase is a potent chemoattractant for human monocytes and neutrophils. J. Leukoc. Biol. 2000; 67: 585-589.
74. Dell'Italia LJ, Husain A,. Dissecting the role of chymase in angiotensin II formation and heart and blood vessel diseases. Curr. Opin. Cardiol. 2002; 17: 374-379.
75. Ruiz-Ortega M, Rupérez M, Esteban V, et al. Angiotensin II: A key factor in the inflammatory and fibrotic response in kidney diseases. Nephrol. Dial. Transplant. 2006; 21: 16-20.
76. Abbas A, Lichtman A, Pober J,. Cytokines. Cytokines (chapter 11). In: Cellular and Molecular Immunology. Philadelphia: WB Saunders Company, 2000; 235-269.
77. Grantham JJ,. Pathogenesis of autosomal dominant polycystic kidney disease: Recent developments. Contrib. Nephrol. 1997; 122: 1-9.
78. Deshmane SL, Kremlev S, Amini S, Sawaya BE,. Monocyte chemoattractant protein-1 (MCP-1): An overview. J. Interferon Cytokine Res. 2009; 29: 313-326.
79. Yadav A, Saini V, Arora S,. MCP-1: Chemoattractant with a role beyond immunity: A review. Clin. Chim. Acta 2010; 411: 1570-1579.
80. Wada T, Furuichi K, Sakai N, et al. Up-regulation of monocyte chemoattractant protein-1 in tubulointerstitial lesions of human diabetic nephropathy. Kidney Int. 2000; 58: 1492-1499.
81. Haberstroh U, Pocock J, Gomez-Guerrero C, et al. Expression of the chemokines MCP-1/CCL2 and RANTES/CCL5 is differentially regulated by infiltrating inflammatory cells. Kidney Int. 2002; 62: 1264-1276.
82. Zheng D, Wolfe M, Cowley BD Jr, Wallace DP, Yamaguchi T, Grantham JJ,. Urinary excretion of monocyte chemoattractant protein-1 in autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 2003; 14: 2588-2595.
83. Chapman AB, Bost JE, Torres VE, et al. Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin. J. Am. Soc. Nephrol. 2012; 7: 479-486.
84. Swenson-Fields K, Vivian C, Wallace DP, Fields T,. MCP-1 is the primary macrophage recruitment factor produced by human and mouse polycystic kidney cells and promotes disease progression in cpk mice. J. Am. Soc. Nephrol. 2012; 23: 48A (Abstract No. FR-OR083).
85. Mazzali M, Kipari T, Ophascharoensuk V, Wesson JA, Johnson R, Hughes J,. Osteopontin-a molecule for all seasons. QJM 2002; 95: 3-13.
86. Wolak T, Kim H, Ren Y, Kim J, Vaziri ND, Nicholas SB,. Osteopontin modulates angiotensin II-induced inflammation, oxidative stress, and fibrosis of the kidney. Kidney Int. 2009; 76: 32-43.
87. Li X, Magenheimer BS, Xia S, et al. A tumor necrosis factor-alpha- mediated pathway promoting autosomal dominant polycystic kidney disease. Nat. Med. 2008; 14: 863-868.
88. Gardner KD Jr, Burnside JS, Elzinga LW, Locksley RM,. Cytokines in fluids from polycystic kidneys. Kidney Int. 1991; 39: 718-724.
89. Partsch G, Steiner G, Leeb BF, Dunky A, Bröll H, Smolen JS,. Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J. Rheumatol. 1997; 24: 518-523.
90. De Groote D, Grau G, Dehart I, Franchimont P,. Stabilisation of functional tumor necrosis factor-alpha by its soluble TNF receptors. Eur. Cytokine Netw. 1993; 4: 359-362.
91. Dell KM, Nemo R, Sweeney WE Jr, Levin JI, Frost P, Avner ED,. A novel inhibitor of tumor necrosis factor-α converting enzyme ameliorates polycystic kidney disease. Kidney Int. 2001; 60: 1240-1248.
92. Gabay C, Lamacchia C, Palmer G,. IL-1 pathways in inflammation and human diseases. Nat. Rev. Rheumatol. 2010; 6: 232-241.
93. Sugimoto Y, Narumiya S,. Prostaglandin E receptors. J. Biol. Chem. 2007; 282: 11613-11617.
94. Grantham JJ, Geiser JL, Evan AP,. Cyst formation and growth in autosomal dominant polycystic kidney disease. Kidney Int. 1987; 31: 1145-1152.
95. Ravine D, Forrest S, Sheffield L, et al. Phenotype and genotype heterogeneity in autosomal dominant polycystic kidney disease. Lancet 1992; 340: 1330-1333.
96. San Millán JL, Viribay M, Peral B, Martínez I, Weissenbach J, Moreno F,. Refining the localization of the PKD2 locus on chromosome 4q by linkage analysis in Spanish families with autosomal dominant polycystic kidney disease type 2. Am. J. Hum. Genet. 1995; 56: 248-253.
97. Nauli SM, Alenghat FJ, Luo Y, et al. Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells. Nat. Genet. 2003; 33: 129-137.
98. Shyy JY, Lin MC, Han J, Lu Y, Petrime M, Chien S,. The cis-acting phorbol ester '12-O-tetradecanoylphorbol 13-acetate'-responsive element is involved in shear stress-induced monocyte chemotactic protein 1 gene expression. Proc. Natl Acad. Sci. U.S.A. 1995; 92: 8069-8073.
99. Shyy YJ, Hsieh HJ, Usami S, Chien S,. Fluid shear stress induces a biphasic response of human monocyte chemotactic protein 1 gene expression in vascular endothelium. Proc. Natl Acad. Sci. U.S.A. 1994; 91: 4678-4682.
100. Flores D, Battini L, Gusella GL, Rohatgi R,. Fluid shear stress induces renal epithelial gene expression through polycystin-2-dependent trafficking of extracellular regulated kinase. Nephron Physiol. 2011; 117: 27-36.
101. Zhou J,. Polycystins and primary cilia: Primers for cell cycle progression. Annu. Rev. Physiol. 2009; 71: 83-113.
102. Mason SB, Lai X, Ringham HN, et al. Differential expression of renal proteins in a rodent model of meckel syndrome. Nephron Exp. Nephrol. 2011; 117: e31-38.
103. Prasad S, McDaid JP, Tam FWK, Haylor JL, Ong ACM,. Pkd2 dosage influences cellular repair responses following ischemia-reperfusion injury. Am. J. Pathol. 2009; 175: 1493-1503.
104. Song X, Di Giovanni V, He N, et al. Systems biology of autosomal dominant polycystic kidney disease (ADPKD): Computational identification of gene expression pathways and integrated regulatory networks. Hum. Mol. Genet. 2009; 18: 2328-2343.
105. Hayden MS, Ghosh S,. NF-κB, the first quarter-century: Remarkable progress and outstanding questions. Genes Dev. 2012; 26: 203-234.
106. Pahl HL,. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 1999; 18: 6853-6866.
107. Qin S, Taglienti M, Cai L, Zhou J, Kreidberg JA,. c-Met and NF-κB-dependent overexpression of Wnt7a and -7b and Pax2 promotes cystogenesis in polycystic kidney disease. J. Am. Soc. Nephrol. 2012; 23: 1309-1318.
108. Wendt T, Tanji N, Guo J, et al. Glucose, Glycation, and RAGE: Implications for amplification of cellular dysfunction in diabetic nephropathy. J. Am. Soc. Nephrol. 2003; 14: 1383-1395.
109. Goyette J, Geczy CL,. Inflammation-associated S100 proteins: New mechanisms that regulate function. Amino Acids 2011; 41: 821-842.
110. Bacallao RL, McNeill H,. Cystic kidney diseases and planar cell polarity signaling. Clin. Genet. 2009; 75: 107-117.
111. Torres M, Gomez-Pardo E, Dressler GR, Gruss P,. Pax-2 controls multiple steps of urogenital development. Development 1995; 121: 4057-4065.
112. Horster MF, Braun GS, Huber SM,. Embryonic renal epithelia: Induction, nephrogenesis, and cell differentiation. Physiol. Rev. 1999; 79: 1157-1191.
113. Schindler C, Levy DE, Decker T,. JAK-STAT signaling: From interferons to cytokines. J. Biol. Chem. 2007; 282: 20059-20063.
114. Bhunia AK, Piontek K, Boletta A, et al. PKD1 induces p21waf1 and regulation of the cell cycle via direct activation of the JAK-STAT signaling pathway in a process requiring PKD2. Cell 2002; 109: 157-168.
115. Davey GM, Heath WR, Starr R,. SOCS1: A potent and multifaceted regulator of cytokines and cell-mediated inflammation. Tissue Antigens 2006; 67: 1-9.
116. Kluth DC, Erwig L-P, Rees AJ,. Multiple facets of macrophages in renal injury. Kidney Int. 2004; 66: 542-557.
117. Metcalf D, Mifsud S, Di Rago L, Nicola NA, Hilton DJ, Alexander WS,. Polycystic kidneys and chronic inflammatory lesions are the delayed consequences of loss of the suppressor of cytokine signaling-1 (SOCS-1). Proc. Natl Acad. Sci. U.S.A. 2002; 99: 943-948.
118. Gattone VH, Cowley BD Jr, Barash BD, et al. Methylprednisolone retards the progression of inherited polycystic kidney disease in rodents. Am. J. Kidney Dis. 1995; 25: 302-313.
119. Dai B, Liu Y, Mei C, et al. Rosiglitazone attenuates development of polycystic kidney disease and prolongs survival in Han:SPRD rats. Clin. Sci. 2010; 119: 323-333.
120. Norman J,. Fibrosis and progression of autosomal dominant polycystic kidney disease (ADPKD). Biochim. Biophys. Acta, Mol. Basis Dis. 2011; 1812: 1327-1336.
121. Wynn TA, Barron L,. Macrophages: Master regulators of inflammation and fibrosis. Semin. Liver Dis. 2010; 30: 245-257.
122. Persy VP, Verhulst A, Ysebaert DK, De Greef KE, De Broe ME,. Reduced postischemic macrophage infiltration and interstitial fibrosis in osteopontin knockout mice. Kidney Int. 2003; 63: 543-553.
123. Wann AKT, Knight M,. Primary cilia elongation in response to interleukin-1 mediates the inflammatory response. Cell. Mol. Life Sci. 2012; 69: 2967-2977.
124. Nahrendorf M, Swirski FK, Aikawa E, et al. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J. Exp. Med. 2007; 204: 3037-3047.
125. Otrock ZK, Mahfouz RAR, Makarem JA, Shamseddine AI,. Understanding the biology of angiogenesis: Review of the most important molecular mechanisms. Blood Cells Mol. Dis. 2007; 39: 212-220.
126. Arnold L, Henry A, Poron F, et al. Inflammatory monocytes recruited after skeletal muscle injury switch into antiinflammatory macrophages to support myogenesis. J. Exp. Med. 2007; 204: 1057-1069.
127. Bogdan C, Vodovotz Y, Nathan C,. Macrophage deactivation by interleukin 10. J. Exp. Med. 1991; 174: 1549-1555.
128. Rang HP, Dale MM, Ritter JM,. Anti-inflammatory and immunosuppressant drugs. In: Rang & Dale's Pharmacology [electronic book], 7th edn. St Louis: Churchill Livingstone, 2012; 318-335.
129. Rhen T, Cidlowski JA,. Antiinflammatory action of glucocorticoids-New mechanisms for old drugs. N. Engl. J. Med. 2005; 353: 1711-1723.
130. Yang Y, Wang J, Qin L, et al. Rapamycin prevents early steps of the development of diabetic nephropathy in rats. Am. J. Nephrol. 2007; 27: 495-502.
131. Bonegio RGB, Fuhro R, Wang Z, et al. Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy. J. Am. Soc. Nephrol. 2005; 16: 2063-2072.
132. Zhang T, Wang L, Xiong X, Mao Z, Wang L, Mei C,. Mycophenolate mofetil versus rapamycin in Han:SPRD rats with polycystic kidney disease. Biol. Res. 2009; 42: 437-444.
133. Jiang S, Tang Q, Rong R, et al. Mycophenolate mofetil inhibits macrophage infiltration and kidney fibrosis in long-term ischemia-reperfusion injury. Eur. J. Pharmacol. 2012; 688: 56-61.
134. Kawai T, Masaki T, Doi S, et al. PPAR-γ agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-β. Lab. Invest. 2008; 89: 47-58.
135. Yoshihara D, Kurahashi H, Morita M, et al. PPAR-gamma agonist ameliorates kidney and liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease. Am. J. Physiol. Renal Physiol. 2011; 300: F465-474.
136. Sankaran D, Bankovic-Calic N, Ogborn MR, Crow G, Aukema HM,. Selective COX-2 inhibition markedly slows disease progression and attenuates altered prostanoid production in Han:SPRD-cy rats with inherited kidney disease. Am. J. Physiol. Renal Physiol. 2007; 293: F821-830.
137. Ruiz-Ortega M, Lorenzo O, Suzuki Y, Rupérez M, Egido J,. Proinflammatory actions of angiotensins. Curr. Opin. Nephrol. Hypertens. 2001; 10: 321-329.
138. Tanifuji C, Suzuki Y, Geot WM, Horikoshi S, Takahashi H, Tomino Y,. Beneficial effects of combination therapy with olmesartan and azelnidipine in murine polycystic kidneys. Kidney Blood Press. Res. 2009; 32: 239-249.
139. Perico N, Zoja C, Corna D, et al. V1/V2 Vasopressin receptor antagonism potentiates the renoprotection of renin-angiotensin system inhibition in rats with renal mass reduction. Kidney Int. 2009; 76: 960-967.
140. Wang X, Gattone V, Harris PC, Torres VE,. Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. J. Am. Soc. Nephrol. 2005; 16: 846-851.
141. Ghosh SS, Massey HD, Krieg R, et al. Curcumin ameliorates renal failure in 5/6 nephrectomized rats: Role of inflammation. Am. J. Physiol. Renal Physiol. 2009; 296: F1146-1157.
142. Leonhard WN, van der Wal A, Novalic Z, et al. Curcumin inhibits cystogenesis by simultaneous interference of multiple signaling pathways: In vivo evidence from a Pkd1-deletion model. Am. J. Physiol. Renal Physiol. 2011; 300: F1193-1202.
143. Zhou Z-L, Yang Y-X, Ding J, Li Y-C, Miao Z-H,. Triptolide: Structural modifications, structure-activity relationships, bioactivities, clinical development and mechanisms. Nat. Prod. Rep. 2012; 29: 457-475.
144. Chen Z,. Studies on the chemical composition of Tripterygium wilfordii Hook F. In:, Li R, Shu D, (eds). Tripterygium wilfordii Hook F Research and Clinical Application. Beijing: Chinese Academic and Technology Publishers, 1989; 47-74.
145. Tao X, Younger J, Fan FZ, Wang B, Lipsky PE,. Benefit of an extract of Tripterygium Wilfordii Hook F in patients with rheumatoid arthritis: A double-blind, placebo-controlled study. Arthritis Rheum. 2002; 46: 1735-1743.
146. Qiu D, Zhao G, Aoki Y, et al. Immunosuppressant PG490 (triptolide) inhibits T-cell interleukin-2 expression at the level of purine-box/nuclear factor of activated T-cells and NF-κB transcriptional activation. J. Biol. Chem. 1999; 274: 13443-13450.
147. Leuenroth SJ, Okuhara D, Shotwell JD, et al. Triptolide is a traditional Chinese medicine-derived inhibitor of polycystic kidney disease. Proc. Natl Acad. Sci. U.S.A. 2007; 104: 4389-4394.
148. Cheng W-L, Lii C-K, Chen H-W, Lin T-H, Liu K-L,. Contribution of conjugated linoleic acid to the suppression of inflammatory responses through the regulation of the NF-κB pathway. J. Agric. Food Chem. 2003; 52: 71-78.
149. Bassaganya-Riera J, Hontecillas R, Beitz DC,. Colonic anti-inflammatory mechanisms of conjugated linoleic acid. Clin. Nutr. 2002; 21: 451-459.
150. Ogborn MR, Nitschmann E, Bankovic-Calic N, Weiler HA, Fitzpatrick-Wong S, Aukema HM,. Dietary conjugated linoleic acid reduces PGE2 release and interstitial injury in rat polycystic kidney disease. Kidney Int. 2003; 64: 1214-1221.
151. Halvorson C, Bremmer M, Jacobs S,. Polycystic kidney disease: Inheritance, pathophysiology, prognosis, and treatment. Int. J. Nephrol. Renovasc. Dis. 2010; 3: 69-83.
152. Nakamura T, Sato E, Fujiwara N, et al. Changes in urinary albumin excretion, inflammatory and oxidative stress markers in ADPKD patients with hypertension. Am. J. Med. Sci. 2012; 343: 46-51.
153. Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N. Engl. J. Med. 2012; 367: 2407-2418.